API | bitopertin

bitopertin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Bitopertin is a glycine reuptake inhibitor which was under development by Roche as an adjunct to antipsychotics for the treatment of persistent negative symptoms or suboptimally controlled positive symptoms associated with schizophrenia. Research into this indication has been largely halted as a result of disappointing trial results. ^Wikipedia

Chemistry

SMILES: C[C@H](Oc1ccc(cc1C(=O)N2CCN(CC2)c3ncc(cc3F)C(F)(F)F)S(=O)(=O)C)C(F)(F)F
InChIKey: YUUGYIUSCYNSQR-LBPRGKRZSA-N
Mol. Mass: 543.46
ALogP: 3.94 Partition coefficient
ChEMBL Molecules:

None

bitopertin

More Chemistry

Pharmacology

Mechanism of Action:
- Sodium- and chloride-dependent glycine transporter 1 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

(4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone | bitopertin | rg1678 | rg 1678 | rg-1678 | ro4917838 | ro-4917838

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

beta-Thalassemia (Phase 2)

Healthy Volunteers (Phase 1)

Obsessive-Compulsive Disorder (Phase 2)

Schizophrenia (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 24
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue